Pfizer is currently running trials for an extended-release, once-a-day version of its $4 billion blockbuster Lyrica. So far, the big pharma has seen mixed results, exceeding in treating fibromyalgia but failing to reduce epileptic seizure frequency, as it attempts to expand the drug's competitiveness against not just current foes like once-daily Cymbalta, but also future cheaper generics.
See more in the following video.
